What Ariflam Treats: Main Uses and Benefits

Ariflam is generally used to provide supportive relief in conditions presenting with systemic or localized discomfort and symptoms related to inflammatory or irritative states. It is applied across therapeutic domains involving distressing manifestations, and is relevant for easing symptoms related to pain and inflammation in conditions such as Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, and Primary Dysmenorrhea.

Managing Symptom Clusters and Functional Stability

Ariflam is commonly used across conditions characterized by periods of heightened symptoms. It is applied in addressing both the pain and the swelling that contributes to stiffness, which supports patients in maintaining functional stability and provides support that may help ease the overall symptom burden. This is relevant in clinical settings involving acute symptom patterns, such as post-operative pain or discomfort from musculoskeletal injuries (e.g., sprains), and during episodic occurrences like acute Migraine attacks.

Quick Fact: Relief for Pain and Inflammation

Ariflam is often used during phases when symptoms intensify and supportive relief is needed, and may assist with maintaining functional stability by addressing inflammatory symptoms that interfere with routine activities.

Ariflam, which contains diclofenac, is an NSAID with specific eligibility rules established by government regulatory bodies. Use is strictly limited or prohibited for certain populations and pre-existing medical conditions.

Populations Who Must NOT Use Ariflam (Contraindicated)

Category	Contraindication Status
Allergy	Known hypersensitivity to diclofenac, aspirin, or other NSAIDs, including a history of allergic-type reactions (e.g., asthma, urticaria).
Gastrointestinal	Active or history of recurrent peptic ulceration, gastrointestinal bleeding, or perforation.
Cardiovascular	Established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease.
Surgery	Treatment of pain just before or after Coronary Artery Bypass Graft (CABG) surgery.
Organ Failure	Severe hepatic failure or severe renal failure.
Pregnancy	The third trimester of pregnancy (starting at 30 weeks gestation).

Populations Requiring Restricted Use

• Elderly Patients (65+): Use requires particular caution and close medical surveillance due to increased risk of serious gastrointestinal and cardiovascular events.
• High Cardiovascular Risk: Patients with risk factors like hypertension, high cholesterol, or diabetes should be treated only after careful consideration, utilizing the lowest effective dose for the shortest duration.
• Non-Severe Impairment: Patients with pre-existing, but non-severe, hepatic, renal, or cardiac function impairment require careful monitoring.
• Pregnancy (First/Second Trimester): Use should generally be avoided unless medically essential.

Age-Specific Eligibility

Eligibility for children and adolescents varies by the specific formulation. Oral formulations are generally suitable for adolescents aged 14 and older, while use in younger children is restricted, with safety and efficacy not established for certain formulations in the pediatric population.

Interactions with other medicines and products

Ariflam (Diclofenac) has officially documented interaction patterns that span several medicinal categories, based strictly on government regulatory labeling.

Interaction-Related Restrictions

Co-administration with other non-Aspirin Non-Steroidal Anti-inflammatory Drugs (NSAIDs) or Ketorolac is not recommended due to a documented increase in the risk of serious gastrointestinal adverse events. Use is formally contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery, and in patients with known NSAID- or Aspirin-sensitive asthma. Certain oral formulations may experience a reduced rate of absorption and effectiveness if taken with food.

Pharmacodynamic and Exposure Interactions

Concurrent use with Anticoagulants, Antiplatelet agents, SSRIs, or SNRIs is documented to result in an increased risk of bleeding. The consumption of Alcohol or the use of Ginkgo Biloba is likewise noted to increase the risk of gastrointestinal bleeding.

Co-administration with Diuretics, ACE Inhibitors, or ARBs can diminish the efficacy of the co-administered medicine and is documented to heighten the risk of severe renal function deterioration. This risk is of heightened clinical significance in elderly or volume-depleted populations. Furthermore, a pharmacokinetic interaction occurs with CYP2C9 inhibitors such as Voriconazole, which increases the plasma exposure of Diclofenac. Diclofenac is also documented to decrease the clearance of co-administered medicines, resulting in officially noted increased plasma levels of substances including Lithium, Digoxin, and Methotrexate.

How Ariflam Works

Ariflam functions as an allosteric modulator, establishing a highly selective binding affinity for the P2 Y12 receptor located on platelet surfaces. This interaction defines the biological target for the drug's activity.

The mechanism proceeds via the allosteric modulation of the P2 Y12 receptor, consequently inhibiting the Gi-protein-coupled downstream signaling pathway. This intracellular cascade prevents the subsequent inhibition of cAMP (cyclic adenosine monophosphate) and blocks the molecular signals required for full platelet activation.

This inhibition restricts downstream platelet activation and aggregation, modifying the cellular response to ADP (adenosine diphosphate) stimuli. This molecular action constitutes the system-level physiological modulation of the P2 Y12 receptor pathway.

Administration Guidelines and Dosing Principles

Ariflam, containing Diclofenac, is administered via several approved routes, including Oral (tablets, solution), Topical (gel, solution), Rectal (suppositories), and Intravenous (IV) injection, with the choice depending on the required systemic or localized effect.

The governing principle for use is to employ the lowest effective dose for the shortest duration consistent with the labeled treatment goals.

Dosing and Frequency Patterns

Indication (Oral Systemic)	Typical Daily Dose Range	Frequency Pattern
Osteoarthritis	100 mg – 150 mg	Divided two or three times daily
Rheumatoid Arthritis	150 mg – 200 mg	Divided three or four times daily
Acute Pain (IV)	37.5 mg (max 150 mg daily)	Administered every six hours as needed

For oral delayed-release tablets, the maximum daily dose generally does not exceed 150 mg for Osteoarthritis or 225 mg for Rheumatoid Arthritis. Extended-release oral forms are typically designated for once-daily dosing.

Procedural and Population-Specific Instructions

Oral tablets, especially delayed-release and extended-release forms, must be swallowed whole and must not be crushed, split, or chewed, to maintain the intended release profile. While most oral systemic forms may be taken with or without food, certain preparations like the oral solution powder are taken on an empty stomach and mixed only with water.

In special populations, such as older adults, treatment is typically initiated at the lower end of the dosing range and for the shortest duration. Due to the rate of metabolism, caution and potential dose reduction may be required for patients with hepatic impairment.

Research evidence / Overview of Studies for Ariflam

Research exploring Ariflam (Diclofenac) was studied for its use in conditions characterized by fluctuating or episodic manifestations like Osteoarthritis (OA) and Rheumatoid Arthritis (RA). This research has been conducted primarily through short-term Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies focused on populations of adults with diagnosed conditions involving periods of heightened symptoms, such as joint pain and inflammation.

For Osteoarthritis, research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level (measured by indices for stiffness and disability). Findings describe patterns observed in the studies related to how symptoms evolved in the observed populations over defined time intervals. For Rheumatoid Arthritis, research also examined outcomes related to physical discomfort, alongside standardized measures of disease activity, like joint swelling and tenderness, in adult populations. Longer follow-up exists primarily to track long-term patient responses and follow-up data.

Sub-Evidence: Studies for Ankylosing Spondylitis

Research was also evaluated in patients with Ankylosing Spondylitis, a condition linked to inflammatory or irritative states and functional limitations. Studies monitored outcomes linked to inflammatory or irritative states, specifically focusing on standardized indices that measure spinal pain, stiffness, and overall mobility. Research highlights what is known about symptom patterns, but there is limited information for long-term structural or functional outcomes.

Evidence for Use in Acute Symptomatic Relief

Ariflam was studied for its application in conditions characterized by fluctuating or episodic manifestations, such as pain after surgery or sudden injuries, and Primary Dysmenorrhea. The research structure for acute pain typically involves single-dose or very short-term RCTs. Research explored outcomes related to physical discomfort, including the time to onset of effect and patient-reported outcomes describing perceived discomfort. Results apply only to the specific, acute populations studied and follow-up durations were limited.

What is Still Uncertain About Ariflam Research

Scientific literature highlights areas where research is ongoing or where certainty remains low: Long-term effects are not fully established, and there is limited information for outcomes regarding sustained changes in daily functioning. Data for certain groups remain insufficient, and subgroup findings are uncertain, especially for pediatric populations and those with specific concurrent health conditions.

Key Studies & References

1. Safety review of diclofenac - Therapeutic Goods Administration (TGA)

Common questions about Ariflam (FAQ)

Q: Can Ariflam be crushed or split if it's a tablet?

A: Oral formulations, such as delayed-release, extended-release, and enteric-coated tablets, are generally intended to be swallowed whole. Regulatory documents advise against crushing, chewing, or splitting these specific types of tablets. This action helps ensure the drug’s intended release profile is maintained, as altering the form may affect how the medicine works or increase the risk of adverse effects.

Q: How long does it typically take for Ariflam to start working?

A: For acute pain relief, the effects of Ariflam may begin relatively quickly after administration. However, when used for chronic inflammatory conditions, the full effects may take several weeks to be fully realized. This pattern is noted in studies related to its use for long-term conditions.

Q: How long does the effect of one dose of Ariflam usually last?

A: The terminal plasma half-life of the active ingredient is typically short, ranging from 1 to 2 hours, which indicates the time needed for half of the dose to be eliminated from the plasma. The duration of symptomatic relief can vary between individuals and depends on the specific dosage form and the condition being managed.

Q: Can Ariflam cause stomach upset, and what helps minimize it?

A: Stomach upset, pain, and irritation are common adverse effects reported with this medicine. Patient information sometimes suggests taking the medicine with food or milk to help manage stomach discomfort. Avoiding rich or spicy foods may also be noted in patient guidance.

Q: Why is it recommended to take Ariflam with food?

A: Taking certain formulations with food is mentioned in guidance to potentially help minimize gastrointestinal discomfort. However, it is important to note that some specialized formulations, such as the oral solution powder, are specifically instructed in regulatory documents to be taken on an empty stomach to ensure proper absorption.

Q: Is it normal to feel a bit dizzy after taking Ariflam?

A: Yes, dizziness is a common side effect reported in clinical trials, occurring in 1% to 10% of patients. Vertigo, a sensation of spinning, is also a reported adverse reaction. These effects are recognized in official product information.

Q: Is Ariflam known to cause drowsiness?

A: Drowsiness (somnolence) has been reported as an adverse reaction in clinical experience with the active ingredient. Because drowsiness has been reported, patients are often advised to be aware of their personal response before performing activities that require concentration.

Q: Can older adults generally use Ariflam safely?

A: Official warnings indicate that use in adults aged 65 and older requires particular caution and close medical monitoring. This is due to a potentially higher risk for serious side effects, including gastrointestinal bleeding and heart problems. Regulatory documents emphasize that treatment for this population should be initiated at the lower end of the dosing range.

Q: Can I take Ariflam if I'm already taking a blood pressure medication?

A: Regulatory documents indicate that taking Ariflam alongside certain blood pressure medicines, such as ACE inhibitors, ARBs, or diuretics, may reduce the effectiveness of those medicines. This combination may increase the risk of severe renal (kidney) function deterioration. Therefore, medical guidance may recommend careful monitoring.

Q: Does Ariflam affect the effectiveness of birth control pills?

A: The medicine itself is generally not known to directly interact with hormonal contraceptives. However, patient guidance advises that if a person experiences vomiting or severe diarrhea while taking oral contraceptives, the birth control pill may not be fully effective.

Q: Can Ariflam be used for pain after dental work?

A: The active ingredient in Ariflam is formally indicated for the relief of mild to moderate acute pain. This is the general category that includes pain following dental procedures, but it is not listed as a specific primary indication.

Q: Is Ariflam available in different strengths?

A: Yes, the active ingredient is manufactured and supplied in various strengths, such as 25 mg, 50 mg, 75 mg, and 100 mg. These different strengths correspond to various dosage forms like delayed-release and extended-release tablets.

Q: What are the signs that Ariflam might be causing liver problems?

A: Although rare, severe liver injury is a known risk. Patients are advised to look for signs of liver toxicity, including unexplained nausea, fatigue, itching, yellowing of the skin or eyes (jaundice), and pain in the upper right stomach area. Patients are advised to contact a healthcare professional if they notice these symptoms.

Q: Can Ariflam be taken with antacids?

A: Regulatory documents do not list antacids as a specific contraindication for use. However, because certain forms of the medicine may have reduced absorption if taken with food, it is possible that co-administration with other oral agents could also affect how the drug is absorbed.

Q: Can Ariflam cause photosensitivity or increased sensitivity to the sun?

A: Yes, increased sensitivity of the skin to sunlight (photosensitivity) is a reported adverse reaction. Official patient information advises that sun protection and the use of sun screen may be recommended when using this medicine.

Q: Does Ariflam have a risk of cardiovascular side effects?

A: Yes, the medication carries a Boxed Warning from regulatory agencies due to a potentially increased risk of serious cardiovascular thrombotic events. These events include heart attack and stroke, which can be fatal. This risk may increase with higher doses and longer duration of use.

How to Store and Dispose of Ariflam (Diclofenac)

The storage and disposal of Ariflam must strictly adhere to the conditions documented in regulatory labeling to maintain the product's quality and ensure safety.

Official Storage Requirements

Requirement	Condition
Temperature	Store at room temperature, typically not above 25 C for some formulations, and keep from freezing.
Protection	Store in a closed container and protect away from moisture and direct light.
Safety	It is mandatory to keep out of the reach of children.

Disposal Instructions

Unused or expired Ariflam must be disposed of according to national regulatory guidelines. The preferred method is using an authorized drug take-back program. If this is unavailable, non-flush list medicines should be removed from their original containers, mixed with an unappealing substance (e.g., dirt), placed in a sealed bag, and discarded in the household trash, following official safe disposal procedures.